NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 356 filers reported holding NEKTAR THERAPEUTICS in Q1 2019. The put-call ratio across all filers is 1.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $581,377,000 | +2.2% | 17,302,891 | -0.0% | 0.72% | -11.0% |
| Q4 2018 | $568,748,000 | -22.3% | 17,302,925 | +44.2% | 0.81% | -4.4% |
| Q3 2018 | $731,658,000 | +29.6% | 12,002,260 | +3.8% | 0.85% | +26.0% |
| Q2 2018 | $564,512,000 | -50.4% | 11,560,779 | +7.9% | 0.67% | -52.5% |
| Q1 2018 | $1,138,631,000 | +30.5% | 10,715,522 | -26.6% | 1.42% | +34.9% |
| Q4 2017 | $872,185,000 | +46.7% | 14,604,569 | -41.0% | 1.05% | +44.0% |
| Q3 2017 | $594,534,000 | +20.4% | 24,772,230 | -1.9% | 0.73% | +19.8% |
| Q2 2017 | $493,779,000 | -12.4% | 25,257,221 | +5.2% | 0.61% | -10.6% |
| Q1 2017 | $563,534,000 | +83.7% | 24,010,818 | -4.0% | 0.68% | +75.3% |
| Q4 2016 | $306,852,000 | -28.6% | 25,008,320 | +0.0% | 0.39% | -27.8% |
| Q3 2016 | $429,579,000 | +16.1% | 25,004,605 | -3.8% | 0.54% | +11.1% |
| Q2 2016 | $370,056,000 | +3.5% | 26,005,353 | -0.0% | 0.48% | +2.3% |
| Q1 2016 | $357,607,000 | -59.2% | 26,007,761 | -50.0% | 0.47% | -15.4% |
| Q4 2015 | $876,257,000 | +202.8% | 52,003,402 | +97.0% | 0.56% | +43.2% |
| Q3 2015 | $289,344,000 | -11.0% | 26,400,000 | +1.5% | 0.39% | +4.8% |
| Q2 2015 | $325,260,000 | +13.7% | 26,000,000 | 0.0% | 0.37% | +16.9% |
| Q1 2015 | $286,000,000 | -23.8% | 26,000,000 | +7.4% | 0.32% | -23.5% |
| Q4 2014 | $375,100,000 | +27.4% | 24,200,000 | -0.8% | 0.42% | +28.7% |
| Q3 2014 | $294,508,000 | -5.9% | 24,400,000 | 0.0% | 0.32% | -6.6% |
| Q2 2014 | $312,808,000 | +5.8% | 24,400,000 | 0.0% | 0.35% | -0.6% |
| Q1 2014 | $295,728,000 | +13.3% | 24,400,000 | +6.1% | 0.35% | +10.1% |
| Q4 2013 | $261,050,000 | +8.6% | 23,000,000 | 0.0% | 0.32% | -0.3% |
| Q3 2013 | $240,350,000 | -8.3% | 23,000,000 | +1.3% | 0.32% | -15.6% |
| Q2 2013 | $262,185,000 | -47.5% | 22,700,000 | -50.0% | 0.38% | +1.3% |
| Q1 2013 | $499,400,000 | – | 45,400,000 | – | 0.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |